What is the appropriate evaluation and management for a patient with bilirubin, ketones, and protein detected on a urine dip‑stick?

Evaluation and Management of Bilirubin, Ketones, and Protein on Urine Dipstick

When bilirubin, ketones, and protein are all detected on urine dipstick, immediately assess for diabetic ketoacidosis (DKA) in patients with diabetes or SGLT2 inhibitor use, evaluate for hepatobiliary disease if bilirubin is present, and confirm proteinuria with a quantitative spot urine albumin-to-creatinine ratio (ACR).

Immediate Assessment Priority: Ketones

The presence of ketones demands urgent attention, particularly in specific high-risk populations:

• Individuals with type 1 diabetes, history of DKA, or those on SGLT2 inhibitors should measure ketones when experiencing unexplained hyperglycemia or symptoms of ketosis (abdominal pain, nausea) and implement sick day protocols or seek immediate medical care if ketones are elevated 1.

• Urine ketone testing is highly sensitive for DKA with excellent negative predictive value 2. A positive urine ketone result warrants immediate evaluation for DKA, especially when combined with hyperglycemia symptoms.

• For patients on SGLT2 inhibitors, hold the medication during acute illness (nausea, vomiting, diarrhea) and implement the "STOP DKA" protocol: stop SGLT2 inhibitor, test for ketones, maintain fluid and carbohydrate intake, and continue insulin 3.

Clinical Pitfall: Standard urine ketone tests primarily detect acetoacetate but may underestimate total ketone burden because they don't measure β-hydroxybutyrate, which predominates in DKA 1. If clinical suspicion for DKA is high despite negative or trace urine ketones, obtain serum ketone measurement.

Bilirubin Evaluation

Positive urine bilirubin requires hepatobiliary assessment but has important limitations:

• Urine bilirubin can indicate conjugated hyperbilirubinemia from hepatobiliary disease or hemolysis 4.

• However, unexpected positive urine bilirubin results (without recent abnormal liver function tests) have limited clinical utility 5. In one study, only 0.13% of all urine tests yielded unexpected positives, though 85% of these patients subsequently had abnormal liver function tests.

• Order liver function tests (AST, ALT, GGT, total bilirubin) to confirm clinical significance 5. The high false-positive rate of dipstick bilirubin testing necessitates laboratory confirmation before extensive workup.

Proteinuria Confirmation and Management

Dipstick proteinuria requires quantitative confirmation:

• A dipstick result of ≥1+ should be followed by a spot urine albumin-to-creatinine ratio (ACR) 4, 6.

• Dipstick testing at ≥1+ has 95.4% specificity for ACR ≥30 mg/g but only 57.8% sensitivity, with a positive predictive value of 47.2% 6. This means nearly half of positive dipsticks will not confirm significant albuminuria on quantitative testing.

• A negative dipstick result (<1+) has 97.6% negative predictive value for ACR ≥30 mg/g and 100% negative predictive value for ACR ≥300 mg/g, making it excellent for ruling out significant proteinuria 6.

For Confirmed Proteinuria (ACR ≥30 mg/g):

In patients with type 2 diabetes and eGFR >25 mL/min/1.73 m²:

1. Initiate or optimize RAS inhibitor (ACE inhibitor or ARB) therapy first 3
2. Add SGLT2 inhibitor as the next priority for patients with eGFR >20 mL/min/1.73 m² and albuminuria, as these agents provide the largest effect on reducing both kidney and cardiovascular outcomes 3
3. Consider nonsteroidal mineralocorticoid receptor antagonist (MRA) for persistent albuminuria despite maximum tolerated RAS inhibitor, particularly in high-risk patients with type 2 diabetes 3

Integrated Clinical Algorithm

Step 1: Assess ketones urgently

• If positive + symptoms → evaluate for DKA immediately
• If patient on SGLT2 inhibitor → hold medication, implement sick day protocol

Step 2: Evaluate bilirubin

• Order liver function tests if clinically indicated
• Recognize high false-positive rate; don't pursue extensive workup without LFT confirmation

Step 3: Confirm proteinuria

• Order spot urine ACR for any dipstick ≥1+
• If ACR ≥30 mg/g confirmed → initiate kidney-protective therapy per algorithm above

Step 4: Monitor potassium when initiating kidney-protective medications

• Select patients with consistently normal potassium for nonsteroidal MRA therapy 3
• Monitor regularly after initiation to mitigate hyperkalemia risk